시판 후 약물감시 및 의료 정보 시장 보고서(2026년)
Post-Marketing Pharmacovigilance And Medical Information Global Market Report 2026
상품코드 : 1957679
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,777,000
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,796,000
PDF & Excel (Site License) help
PDF & Excel 보고서를 동일 기업의 동일 사업장 내의 모든 분이 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,815,000
PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

시판 후 약물감시 및 의료 정보 시장 규모는 최근 급성장하고 있습니다. 2025년 69억 달러에서 2026년에는 77억 1,000만 달러에 이르고, CAGR 11.7%의 성장이 전망되고 있습니다. 과거 성장 요인으로는 시판 후 조사 인프라 부족, 수동 부작용 보고에 대한 의존, 의약품 안전에 대한 규제 요건 강화, 신약 승인 건수 증가, 통합된 병원 데이터 시스템 부족 등을 들 수 있습니다.

시판 후 약물감시 및 의료 정보 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 118억 9,000만 달러에 이르고, CAGR은 11.4%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 AI 및 머신러닝 알고리즘의 신호 감지 통합, 종단적 환자 데이터 분석 도입, 질병 등록 데이터베이스 연동 모니터링 확대, 디지털 앱 기반 보고 증가, 실시간 약물감시 기술 투자 확대 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 전자건강기록(EHR) 마이닝 도입 확대, 실시간 약물유해반응(ADR) 모니터링 시스템 사용 증가, 위험군 기반 및 치료군 기반 보고의 성장, 신규 의약품 사용자에 대한 코호트 이벤트 모니터링 확대, 디지털 및 모바일 플랫폼의 통합 등이 있습니다. 약물감시 보고를 위한 디지털 및 모바일 플랫폼의 통합 등이 포함됩니다.

약물 부작용 증가율은 향후 시판 후 약물감시 및 의료 정보 시장을 가속화할 것으로 예측됩니다. 부작용은 예방, 진단, 치료 목적으로 통상적인 용량으로 사용된 의약품에서 발생하는 부작용 또는 예상치 못한 반응을 말합니다. 고령화가 진행되고 여러 만성질환을 다약제 병용요법으로 관리하는 환자가 증가함에 따라 약물 상호작용과 예상치 못한 부작용의 발생 빈도가 증가하고 있습니다. 시판 후 약물감시 및 의료정보는 시판 후 부작용 데이터를 식별, 기록, 공유함으로써 의약품의 안전성과 유용성을 유지하여 이러한 문제를 해결합니다. 예를 들어, 2023년 1월 미국의 인공지능(AI) 기반 IT 서비스 기업 나비켄츠(Navicentz)가 발표한 추산에 따르면, 미국 내 약물 부작용으로 인한 사망자 수는 연간 20만-40만 명에 달하며, 이는 뇌졸중과 당뇨병으로 인한 사망자 수를 합친 것보다 더 많은 수치입니다. 또한, 270만 건의 약물 부작용 사례가 발생하여 10만 명 이상의 입원 및 1만 5천 명 이상의 사망을 초래했습니다. 이처럼 급증하는 약물유해반응이 시판 후 약물감시 및 의료정보 시장을 주도하고 있습니다.

시판 후 약물감시 및 의료정보 시장의 주요 기업들은 AI를 활용한 약물감시 워크플로우와 같은 툴을 통해 사건 감지 정확도를 높이고, 우수한 환자 결과를 위한 즉각적인 안전성 모니터링을 실현하고 있습니다. AI를 활용한 약물감시 워크플로는 인공지능을 활용한 자동화된 안전성 모니터링을 통해 신속한 검출과 컴플라이언스 준수를 강화합니다. 예를 들어, 2024년 1월 영국의 클라우드 SaaS 업체인 PubHive Ltd.는 생명과학 및 연구 분야를 위해 제품 요약(SmPC) 중앙 관리 시스템을 도입했습니다. 이 시스템은 중요한 안전 데이터를 하나의 허브에 통합하고, 문헌 스캔 및 보고를 자동화하고, 협업을 촉진하며, AI의 지능을 활용하여 규제 대응을 용이하게 합니다. 이를 통해 팀은 환자를 보호하고 규정을 준수하며, 적극적이고 효율적인 운영을 실현할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

LSH
영문 목차

영문목차

Post-marketing pharmacovigilance involves the ongoing monitoring of a drug's safety after it has been released on the market, aiming to detect, assess, and prevent adverse effects or other drug-related issues. Medical information services provide accurate, scientific, and up-to-date responses to healthcare providers and patients regarding a drug's use, safety, and efficacy. Together, these processes protect patient health, ensure regulatory compliance, and improve treatment outcomes.

The main types of post-marketing pharmacovigilance and medical information include spontaneous reporting, intensified adverse drug reaction (ADR) reporting, targeted spontaneous reporting, cohort event monitoring, and electronic health record (EHR) mining. Spontaneous reporting involves healthcare professionals or patients voluntarily identifying and reporting unexpected reactions linked to medication use to authorized organizations. It includes product formats such as books, online media, and journals, and serves a variety of end users, including hospitals, research organizations, and others.

Tariffs have impacted the post-marketing pharmacovigilance and medical information market by increasing costs of imported software solutions, analytical tools, and digital monitoring platforms. Segments like electronic health record (EHR) mining and real-time ADR monitoring systems are most affected, particularly in North America and Europe where imports are significant. This has led to increased operational costs and slower technology adoption. However, tariffs have encouraged local development of pharmacovigilance platforms, innovation in AI-based monitoring tools, and greater domestic investment in medical information services.

The post-marketing pharmacovigilance and medical information market research report is one of a series of new reports from The Business Research Company that provides post-marketing pharmacovigilance and medical information market statistics, including post-marketing pharmacovigilance and medical information industry global market size, regional shares, competitors with a post-marketing pharmacovigilance and medical information market share, detailed post-marketing pharmacovigilance and medical information market segments, market trends and opportunities, and any further data you may need to thrive in the post-marketing pharmacovigilance and medical information industry. This post-marketing pharmacovigilance and medical information market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The post-marketing pharmacovigilance and medical information market size has grown rapidly in recent years. It will grow from $6.9 billion in 2025 to $7.71 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to limited post-marketing surveillance infrastructure, reliance on manual ADR reporting, growing regulatory requirements for drug safety, increased number of new drug approvals, lack of integrated hospital data systems.

The post-marketing pharmacovigilance and medical information market size is expected to see rapid growth in the next few years. It will grow to $11.89 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to integration of ai and ml algorithms in signal detection, adoption of longitudinal patient data analysis, expansion of disease registry-linked monitoring, increasing digital app-based reporting, rising investments in real-time pharmacovigilance technologies. Major trends in the forecast period include increasing adoption of electronic health record (ehr) mining, rising use of real-time adverse drug reaction (adr) monitoring systems, growth in risk population-based and therapeutic class-based reporting, expansion of cohort event monitoring for new drug users, integration of digital and mobile platforms for pharmacovigilance reporting.

The climbing rate of adverse drug reactions is set to accelerate the post-marketing pharmacovigilance and medical information market ahead. Adverse drug reactions are noxious or unplanned responses from drugs used at normal doses for prevention, diagnosis, or care. Their frequency grows with an aging populace managing multiple chronic issues via polypharmacy, amplifying risks of interactions and surprises. Post-marketing pharmacovigilance and medical information tackle these by spotting, logging, and disseminating post-launch side effect data to uphold drug safety and utility. For example, in January 2023, Navikenz, a US AI-driven IT services firm, estimated US adverse drug reactions claim 200,000-400,000 lives yearly-outpacing stroke and diabetes combined-with 2.7 million cases sparking over 100,000 hospital stays and 15,000+ deaths. Thus, the surging adverse drug reactions are propelling the post-marketing pharmacovigilance and medical information market.

Leading companies in the post-marketing pharmacovigilance and medical information market are advancing tools like AI-powered pharmacovigilance workflows to sharpen event spotting and deliver instant safety oversight for superior patient results. AI-powered pharmacovigilance workflows harness artificial intelligence for automated safety surveillance, hastening detection and bolstering compliance. For instance, in January 2024, PubHive Ltd., a UK cloud SaaS provider, rolled out centralized Summary of Product Characteristics (SmPC) management for life sciences and research. The system unifies vital safety data in one hub, automates lit scanning and reports, fosters collaboration, and eases rules via AI smarts-empowering teams for proactive, efficient ops that safeguard patients and meet regs.

In October 2023, Ergomed plc, a UK pharma services firm, bought Panacea Pharma Projects Limited for an undisclosed sum. This expands Ergomed's PrimeVigilance unit, amps capabilities, and widens reach to cement leadership in pharmacovigilance. Panacea Pharma Projects Limited is a UK consultancy expert in pharmacovigilance (PV) and medical info, including post-market aid.

Major companies operating in the post-marketing pharmacovigilance and medical information market are Accenture plc, Sanofi S.A., Capgemini SE, Merck & Co. Inc., Cognizant Technology Solutions Corporation, IQVIA Holdings Inc., HCL Technologies Limited, ICON plc, Syneos Health Inc., Genpact Limited, Parexel International Corporation, Avalere Health LLC, Quanticate Limited, Inizio Consulting LLC

North America was the largest region in the post-marketing pharmacovigilance and medical information market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-marketing pharmacovigilance and medical information market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the post-marketing pharmacovigilance and medical information market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The post-marketing pharmacovigilance and medical information market includes revenues earned by entities by providing services such as adverse event reporting and management, signal detection and risk assessment, drug safety database, medical call center services, and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Post-Marketing Pharmacovigilance And Medical Information Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses post-marketing pharmacovigilance and medical information market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for post-marketing pharmacovigilance and medical information ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The post-marketing pharmacovigilance and medical information market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

2. Post-Marketing Pharmacovigilance And Medical Information Market Characteristics

3. Post-Marketing Pharmacovigilance And Medical Information Market Supply Chain Analysis

4. Global Post-Marketing Pharmacovigilance And Medical Information Market Trends And Strategies

5. Post-Marketing Pharmacovigilance And Medical Information Market Analysis Of End Use Industries

6. Post-Marketing Pharmacovigilance And Medical Information Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Post-Marketing Pharmacovigilance And Medical Information Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

8. Global Post-Marketing Pharmacovigilance And Medical Information Total Addressable Market (TAM) Analysis for the Market

9. Post-Marketing Pharmacovigilance And Medical Information Market Segmentation

10. Post-Marketing Pharmacovigilance And Medical Information Market Regional And Country Analysis

11. Asia-Pacific Post-Marketing Pharmacovigilance And Medical Information Market

12. China Post-Marketing Pharmacovigilance And Medical Information Market

13. India Post-Marketing Pharmacovigilance And Medical Information Market

14. Japan Post-Marketing Pharmacovigilance And Medical Information Market

15. Australia Post-Marketing Pharmacovigilance And Medical Information Market

16. Indonesia Post-Marketing Pharmacovigilance And Medical Information Market

17. South Korea Post-Marketing Pharmacovigilance And Medical Information Market

18. Taiwan Post-Marketing Pharmacovigilance And Medical Information Market

19. South East Asia Post-Marketing Pharmacovigilance And Medical Information Market

20. Western Europe Post-Marketing Pharmacovigilance And Medical Information Market

21. UK Post-Marketing Pharmacovigilance And Medical Information Market

22. Germany Post-Marketing Pharmacovigilance And Medical Information Market

23. France Post-Marketing Pharmacovigilance And Medical Information Market

24. Italy Post-Marketing Pharmacovigilance And Medical Information Market

25. Spain Post-Marketing Pharmacovigilance And Medical Information Market

26. Eastern Europe Post-Marketing Pharmacovigilance And Medical Information Market

27. Russia Post-Marketing Pharmacovigilance And Medical Information Market

28. North America Post-Marketing Pharmacovigilance And Medical Information Market

29. USA Post-Marketing Pharmacovigilance And Medical Information Market

30. Canada Post-Marketing Pharmacovigilance And Medical Information Market

31. South America Post-Marketing Pharmacovigilance And Medical Information Market

32. Brazil Post-Marketing Pharmacovigilance And Medical Information Market

33. Middle East Post-Marketing Pharmacovigilance And Medical Information Market

34. Africa Post-Marketing Pharmacovigilance And Medical Information Market

35. Post-Marketing Pharmacovigilance And Medical Information Market Regulatory and Investment Landscape

36. Post-Marketing Pharmacovigilance And Medical Information Market Competitive Landscape And Company Profiles

37. Post-Marketing Pharmacovigilance And Medical Information Market Other Major And Innovative Companies

38. Global Post-Marketing Pharmacovigilance And Medical Information Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Post-Marketing Pharmacovigilance And Medical Information Market

40. Post-Marketing Pharmacovigilance And Medical Information Market High Potential Countries, Segments and Strategies

41. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기